Akums Drugs and Pharmaceuticals Ltd

Ticker: AKUMS
Decent 68/100

☆ Add to Watchlist
Rebound

Investing Reference

Price
460.75
Market Cap
7054.18
Debt/Equity
0.0288
ROE %
17.874
PB
2.3026
Promoter %
75.260
Pledge %
0.000
1Y Rev Growth %
-0.599
5Y Rev Growth %
11.389
NP Margin %
8.077
NP Margin 5Y Avg %
1.630

Trading Reference

1M Return %
4.886
6M Return %
-10.983
1Y Return %
-45.273
% Away 52W High
95.898
% Away 52W Low
13.765
Daily Volume
53334
Investment Verdict
Hold
Score 71/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 24/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.

Summary

Akums Drugs and Pharmaceuticals Ltd shows strong growth potential in the Indian pharmaceutical sector, driven by robust demand and strategic expansions.

✅ Positives
  • Strong revenue growth over the past few years
  • Diverse product portfolio across various therapeutic segments
  • Strategic partnerships enhancing market reach

⚠️ Negatives
  • High competition in the pharmaceutical industry
  • Regulatory challenges impacting operations
  • Dependence on a few key clients for revenue

Verdict
Moderate growth potential with manageable risks.
Recommendation: Consider buying for long-term growth.
Upside Probability: 25%   |   Downside Probability: 15%
Last generated: 30/10/2025

More Options

Business Overview

Akums Drugs and Pharmaceuticals Ltd is a leading Indian pharmaceutical manufacturer specializing in contract manufacturing and development of a wide range of pharmaceutical products. Catering primarily to domestic and international markets, Akums plays a crucial role in enhancing healthcare accessibility. With a commitment to quality and innovation, the company contributes significantly to the pharmaceutical landscape in India, ensuring compliance with global standards. Akums is dedicated to improving patient outcomes through its diverse product portfolio.

  • Leading contract manufacturer in India
  • Wide range of pharmaceutical products
  • Focus on quality and innovation
  • Strong compliance with global standards
  • Enhancing healthcare accessibility
  • Significant contributor to India's pharma landscape

Investment Thesis

Akums Drugs and Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company favorably in the evolving pharmaceutical landscape.

  • Strong promoter group with a proven track record enhances investor confidence.
  • Expanding digital services segment poised for robust growth, tapping into modern healthcare trends.
  • Attractive valuation metrics compared to industry peers, offering potential for upside.
  • Established market presence and diverse product portfolio bolster revenue stability.
  • Focus on R&D and innovation positions Akums for long-term competitive advantage.

Opportunity vs Risk

Opportunities
  • Growing demand for pharmaceuticals
  • Strong export potential
  • Government support for healthcare
  • Innovative product pipeline
  • Expanding distribution network
Risks ⚠️
  • Regulatory changes impact
  • Intense market competition
  • Raw material price volatility
  • Dependence on key clients
  • Foreign exchange fluctuations

Peer Perspective

Akums Drugs trades at a discount to peers like Sun Pharmaceutical and Cipla, reflecting its growth potential. A rerating could occur if it achieves consistent margin stability and accelerates revenue growth.

Future Outlook

Akums Drugs and Pharmaceuticals Ltd is well-positioned for growth, driven by strong demand in the healthcare sector. However, successful execution of its expansion plans and effective cost control will be crucial to achieving sustainable profitability.

AI FAQs for Retail Users

  • Q: What does Akums Drugs and Pharmaceuticals Ltd do?
    A: Akums is a leading manufacturer of pharmaceutical formulations and active pharmaceutical ingredients in India.
  • Q: Is Akums Drugs listed on stock exchanges?
    A: Yes, Akums Drugs is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
  • Q: What are the key products of Akums?
    A: Akums produces a wide range of formulations, including tablets, capsules, and injectables across various therapeutic segments.
  • Q: How has Akums performed financially?
    A: For detailed financial performance, please refer to their quarterly and annual reports available on their website.
  • Q: What is the company’s growth strategy?
    A: Akums focuses on expanding its product portfolio and increasing its presence in international markets.
📊 Stock Investment Checklist (100 Points)
Akums Drugs and Pharmaceuticals Ltd • Updated: 2025-09-17 01:09:07
  • 10
    Business
    High
    Pharmaceutical sector is growing, but competition is intense.
  • 10
    Growth
    High
    Consistent revenue growth, but profit margins are under pressure.
  • 10
    Profitability
    High
    ROE and ROCE are decent, but OCF is fluctuating.
  • 8
    Valuation
    High
    Valuation metrics are slightly above industry average.
  • 7
    Balance
    High
    Moderate debt levels, but liquidity is adequate.
  • 6
    Governance
    Good
    Promoter holding is strong, but some pledging exists.
  • 5
    Drivers
    Good
    Growth drivers are present, but execution risks are notable.
  • 5
    Technicals
    Good
    Market sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100 • Decent
Akums Drugs and Pharmaceuticals Ltd shows potential for growth, but faces challenges in profitability and market competition.

AI Confidence Score

Instead of just “overall score,” broken into categories:

  • Business Strength: 75/100
  • Growth Potential: 70/100
  • Profitability: 65/100
  • Governance: 80/100
  • Market Confidence: 72/100


More Like This

Latest News

More ↗

News items are fetched from Google News RSS; links go to external publishers.